Hackensack Meridian Center for Discovery and Innovation | Boosted BCG Vaccine Strategy Significantly Reduces TB Relapse

14 September 2026

Hackensack Meridian Center for Discovery and Innovation news release

TB remains one of the world’s leading causes of death, and preventing post-treatment relapse continues to be a major worldwide health challenge. But a new study reveals that combining an immunotherapy with the traditional Bacille Calmette-Guérin (BCG) vaccine drastically lowers the risk of TB relapse in preclinical models.

The findings outline a promising avenue for strengthening long-term immune control against TB recurrence.

Read the full news release here.

Source: Hackensack Meridian Center for Discovery and Innovation